Cargando…
The association of genomic lesions and PD-1/PD-L1 expression in resected triple-negative breast cancers
BACKGROUND: Elevated PD-L1 expression on tumor cells, a context associated with an adaptive immune response, has been linked to the total burden of copy number variants (CNVs) in aneuploid tumors, to microsatellite instability (MSI), and to specific genomic driver lesions, including loss of PTEN, MY...
Autores principales: | Barrett, Michael T., Lenkiewicz, Elizabeth, Malasi, Smriti, Basu, Anamika, Yearley, Jennifer Holmes, Annamalai, Lakshmanan, McCullough, Ann E., Kosiorek, Heidi E., Narang, Pooja, Wilson Sayres, Melissa A., Chen, Meixuan, Anderson, Karen S., Pockaj, Barbara A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6042255/ https://www.ncbi.nlm.nih.gov/pubmed/29996881 http://dx.doi.org/10.1186/s13058-018-1004-0 |
Ejemplares similares
-
Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer
por: Barrett, Michael T., et al.
Publicado: (2015) -
Unique evolutionary trajectories of breast cancers with distinct genomic and spatial heterogeneity
por: Phung, Tanya N., et al.
Publicado: (2021) -
Unique genomic and neoepitope landscapes across tumors: a study across time, tissues, and space within a single lynch syndrome patient
por: Phung, Tanya N., et al.
Publicado: (2020) -
Antitumor efficacy of combined CTLA4/PD-1 blockade without intestinal inflammation is achieved by elimination of FcγR interactions
por: Bauché, David, et al.
Publicado: (2020) -
Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients
por: Kumar, Sunny, et al.
Publicado: (2022)